Inflammasomes in Cell Death in FTMH, ERM, and RRD

Completed

• Conditions: Full Thickness Macular Hole; Retinal Detachment; Epiretinal Membrane
• Interventions: Procedure: Pars plana vitrectomy; Procedure: External drainage

• Registration Number: NCT03332758
• Lead Sponsor: Allen C. Ho, MD

Brief Summary

Prospective study evaluating the role of inflammasomes in cell death in retinal detachment, full thickness macular hole, and epiretinal membrane. The investigators are collecting vitreous and subretinal fluid samples from patients with these conditions and evaluating activity of the inflammasome pathway with established assays.

Detailed Description

Photoreceptor cell death is the main cause of vision loss in many retinal disorders, including retinal detachment (RD). While apoptosis is the most studied form of cell death, the investigators believe patients with RDs may have photoreceptor cell death from a distinct pathway of programmed cell death called pyroptosis which also involves an inflammatory response. Pyroptosis is distinct from apoptosis in that it requires the activation of a protein oligomer complex called an inflammasome. The inflammasome is a pro-inflammatory complex composed of apoptosis-associated speck-like protein containing a CARD (ASC), nucleotide-binding oligomerization domain-containing protein (NOD)-like receptor (NLR) family or pyrin and HIN domain (PYHIN) family, and caspase-11. Activation of the inflammasome complex leads to activation of capspase 1 proteolytic activity to cleave and synthesize IL-1β and IL-18. As such the investigators believe inflammasomes and its activated products may play a strong role in the inflammatory and cell death pathway for photoreceptor cells in human retina. Studies using animal models of RD have already confirmed the presence of IL-1β activation2, however, the presence of IL-18 needs to be confirmed in human detached retinas. In a study performed on the detached retinas in mice, researchers were able to show activation of inflammasomes leading to photoreceptor cell death. While researchers are unable to determine the cellular source of the inflammasomes they were able to show that activation inflammasomes closely follows animal models. Currently there is no method to rescue photoreceptors cells from the mediated cell death pathway despite surgical intervention. Thus, current visual prognosis and prevention of further photoreceptor loss due to a RD is likely dependent on the time of surgical intervention before further detachment and further cell death can occur. As such, the purpose of this current study is to confirm the presence of inflammasome activation as well as the synthesis of its products, IL-1β and IL-18, in patients with rhegmatogenous retinal detachments. Both inflammasomes and its products IL-1β and IL-18 may be involved in cell pyroptosis, a programmed cell death distinct from apoptosis. Due to a lack of treatment for the rescue of photoreceptor cells from cell death after a retinal detachment, this study can provide novel strategies to inhibit cell death.

Study Timeline

• Study Start: 2017-09-08
• Study First Submitted: 2017-10-13
• Study First Submitted QC: 2017-11-01
• Study First Posted: 2017-11-06
• Primary Completion: 2018-04-10
• Study Completion: 2018-05-01
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-15
• Last Update Posted: 2018-08-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

1. Patient of the Wills Eye Hospital Retina service and Mid-Atlantic Retina offices.
2. Volunteer patients age 18 years and older.
3. Healthy enough to participate in the study.
4. Willing and able to consent to participation in the study.
5. Diagnosis of rhegmatogenous retinal detachment treated with external drainage of subretainl fluid, rhegmatogenous retinal detachment treated with pars plana vitrectomy, or full thickness macular hole treated with pars plana vitrectomy

Read More

Exclusion Criteria

1. Presence of tractional retinal detachment
2. History of trauma
3. Presence of proliferative vitreoretinopathy
4. History of prior retinal detachment repair or any prior retina surgery or laser treatment e. Any preexisting retinal disease (including diabetic retinopathy, age related macular degeneration, retinal vein or artery occlusion, other retinal vascular disease, inherited retinal degeneration, uveitis)

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Macular holes treated with vitrectomy	Pars plana vitrectomy	Vitreous fluid from patients treated for macular hole
ERM treated with vitrectomy	Pars plana vitrectomy	Vitreous fluid from patients treated for epiretinal membrane
RD treated with vitrectomy	Pars plana vitrectomy	Vitreous fluid from retinal detachment treated with pars plana vitrectomy
RD treated with external drainage	External drainage	Subretinal fluid from retinal detachment treated with external drainage.

Primary Outcome Measures

Name	Time	Method
Presence of inflammasomes and their active products	Day of surgery	Presence of inflammasomes and their active products in patients with retinal detachment treated with vitrectomy or external drainage, macular holes treated with vitrectomy, and epiretinal membranes treated with vitrectomy

Secondary Outcome Measures

Name	Time	Method
Difference in inflammasome levels among samples	Day of surgery	Difference in inflammasome pathway activation between retinal detachment, macular hole, and epiretinal membrane samples

Trial Locations

Locations (1)

MidAtlantic Retina-Wills Eye Hospital; 🇺🇸 Philadelphia, Pennsylvania, United States